Amarin’s Vascepa Will Get Two FDA Decisions, But Is That Good News?
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA changes its mind and agrees to review appeal of ANCHOR special protocol assessment rescission, but that doesn’t necessarily mean an ultimate sNDA approval is any more likely.
You may also be interested in...
FDA Makes It Formal, Rescinds SPA For Amarin’s ANCHOR Study
Agency makes clear that triglyceride levels are no longer an acceptable surrogate for reducing cardiovascular risk.
FDA’s Authority Looks Safe From Judicial Interference Following Supreme Court Abortion Pill Arguments
The agency's and the pharma industry’s worst fears – that a potential ruling in the mifepristone case might usurp the FDA’s scientific authority and throw the stability of the US drug approval process into question – seem unlikely to materialize as the majority of the Supreme Court justices signal the Alliance for Hippocratic Medicine lacks standing to sue.
Bernie Gets Mostly Pharma-Friendly Drug Pricing Results
Changes to inhaler pricing may be more ‘business as usual’ for the drug industry than the Vermont senator wants to let on. FTC, meanwhile, is keeping the patent pressure on Teva, the only inhaler manufacturer to not act following Sanders’ investigation.